RMP-A03 Ocular Suspension in Patients With Pterygium

Completed · Phase 2 · Has a placebo group

Conditions studied: Pterygium

In brief

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

Key facts

Study ID

NCT05794204

Run by

Suzhou Raymon Pharmaceuticals Company, Ltd.

People needed

77

Starts

2023-06-09

Expected to finish

2024-01-12

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be at least 18 years old
• Diagnosis of pterygium with specified characteristics
• BCVA of 20/200 or better
• Willingness to attend all study visits and comply with the study procedures

You may not qualify if…

• Presence of ocular disease
• Double pterygium
• History of ocular surgery
• Presence of ocular trauma
• Use of any ocular medication
• Use of contact lens
• Allergy to any of the components of study drug
• Cannot properly administer study drug
• Clinically significant systemic disease that may place the subject at risk or confound study results
• Participation in an investigational study within 30 days prior to screening
• Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).

Where it is running

• Global Research Management — Glendale, California, United States
• United Medical Research Institute — Inglewood, California, United States
• Eye Research Foundation Inc — Newport Beach, California, United States
• Oceane7 Medical & Research Center Inc. — Miami, Florida, United States
• Toyos Clinic — Nashville, Tennessee, United States
• Keystone Research — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.